2025-16905Notice

FDA Backtracks on Withdrawing Amantadine Syrup Approval

Published Date: 9/4/2025

Notice

Summary

The FDA fixed a mistake about pulling approval for eight generic drug applications. One company, CMP Pharma, asked to keep their approval for amantadine syrup, and the FDA agreed, so that drug’s approval stays active. This update clears up confusion and keeps things fair for the companies involved, effective April 14, 2025.

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

FDA Keeps Amantadine Syrup Approval

The FDA corrected a March 14, 2025 notice and kept approval of ANDA 075819 for amantadine hydrochloride syrup, 50 mg/5 mL, held by CMP Pharma, Inc. The original notice said the approval would be withdrawn as of April 14, 2025, but CMP Pharma timely asked to retain approval, so the approval remains in effect.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Effective Date
Published Date
4/14/2025
9/4/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register